Updates

We have advised a medical device manufacturer on the regulatory implications of the restriction on synthetic polymer microparticles for its products.

We have assisted a distributor of medical devices on questions pertaining to a cleaning solution regulated under the Biocidal Product Regulation.

Axon acted on behalf of an investor in connection with their investment in a clinical-stage biotech company developing first-in-class therapeutics and diagnostics for fibrosis. We conducted legal due diligence on the target company and reviewed the transaction documentation on behalf of the investors.

Axon assisted a Dutch cultivated materials company in securing a EUR 22M Series A financing round. We advised on the transaction structure, investment documentation and related matters.

Axon advised a stock-listed biopharmaceutical company on antibody licensing and technology transfer agreements with two major US-based pharmaceutical companies. The deals involved the grant of commercial rights to the licensor's proprietary antibody platform technology.

Axon advised a Dutch joint venture, that is active within the agri-food and agricultural biotechnology sector, on the transfer of its assets to a German investment fund. The transferred assets involved patent rights, plant breeders’ rights, trade secrets and biological materials.

Axon regularly advises spin-outs from academic institutions on a wide range of topics. We make sure that the spin-out’s license agreement includes commercially and legally viable terms and is attractive to investors. In addition, we advise on the corporate structure of the spin-out, balancing the interest of the founders, the academic institution and all other stakeholders.